Kiran Mazumdar Shaw Labels Bengaluru as a ‘Garbage City’, Read Her Full Post
Kiran Mazumdar-Shaw, the Executive Chairperson of Biocon Limited, has expressed her disappointment and concern over the current state of Bengaluru, once known as the “Garden City”. She tweeted a video showcasing the poor condition of Lal Bagh, a prominent park in the city, and lamented that Bengaluru is transforming into a “garbage city”. Mazumdar-Shaw called upon the citizens to take action and work together to restore the city to its former glory.
Her comments come after BJP MP Tejasvi Surya wrote a letter to Bengaluru Incharge Minister DK Shivakumar and BBMP Commissioner Tushar Girinath, highlighting the city’s poor infrastructure. Surya pointed out the deplorable state of roads, potholes, garbage, and broken footpaths, which he believed created a negative image of the city, especially during the recent TCS World 10K race.
Mazumdar-Shaw’s tweet sparked a sense of urgency, as she questioned what had happened to the city’s original planning and vision. She emphasized the need for citizens to take ownership and work towards regaining their city, allowing it to flourish once again. The tweet also tagged the official handles of the Bruhat Bengaluru Mahanagara Palike (BBMP) and the Bangalore Political Action Committee (BPAC), signaling a call to action for the authorities to address the issue.
The criticism from prominent figures like Mazumdar-Shaw and Surya highlights the growing concern over Bengaluru’s deteriorating infrastructure and environmental condition. The city’s rapid growth and urbanization have led to issues such as garbage management, traffic congestion, and poor public amenities. The call to action from Mazumdar-Shaw and Surya serves as a reminder that the citizens and authorities must work together to restore Bengaluru’s former charm and ensure a sustainable future for the city.
Dr Reddy’s, a Hyderabad-based pharma company, set to launch Sanofi’s innovative medication in India, as reported by Telangana Today
Dr. Reddy’s Laboratories has expanded its partnership with Sanofi Healthcare to introduce a novel drug, Beyfortus, for the prevention of lower respiratory tract disease (LRTD) in newborns and infants. Beyfortus contains the monoclonal antibody nirsevimab and is administered via a prefilled injection. The medication is designed to prevent respiratory syncytial virus (RSV) LRTD in newborns and infants, as well as in children up to 24 months of age who are vulnerable to severe RSV disease.
RSV is a highly contagious virus that can lead to serious respiratory illness in infants. Under the partnership, Dr. Reddy’s will have exclusive rights to promote and distribute Beyfortus in India. The company plans to launch the drug in India in the second quarter of the current fiscal year. This announcement follows a successful partnership between Dr. Reddy’s and Sanofi for the distribution of vaccines in India last year.
The introduction of Beyfortus is a significant step in protecting children from immunization-preventable diseases like RSV. The drug has already been approved for use in several countries, including the European Union, the US, China, and Japan. In India, it received marketing authorization approval from the Central Drugs Standard Control Organisation (CDSCO) in June last year.
According to Dr. Reddy’s CEO, MV Ramana, Beyfortus provides healthcare professionals and parents with an improved option for preventing RSV. Nitya Padmanabhan, Head of Sanofi Vaccines (India), noted that bringing Beyfortus to India is a pivotal step in the company’s mission to protect every child from immunization-preventable diseases. The partnership between Dr. Reddy’s and Sanofi aims to increase access to this critical medication and improve the health outcomes of infants and young children in India.
Sun Pharma’s MM-II trial demonstrates sustained pain relief for patients with knee osteoarthritis.
Sun Pharmaceutical Industries Ltd., India’s largest pharmaceutical company, has announced promising results from a clinical trial for MM-II, a new non-opioid therapy for knee osteoarthritis pain relief. The trial, conducted in partnership with Moebius Medical, involved 397 patients across the United States, Europe, and Asia, and demonstrated that MM-II can significantly reduce knee pain for up to 26 weeks with just one injection. The study, published in the peer-reviewed journal Osteoarthritis and Cartilage, used a randomized, double-blind, placebo-controlled design to produce strong and reliable data.
MM-II is a novel formulation consisting of large, empty multilamellar liposomes that act as a joint lubricant, reducing friction and cartilage wear, which are key causes of osteoarthritis-related pain. The treatment not only provided sustained pain relief but also showed promise in creating a protective lubricating coat over cartilage, potentially delaying the progression of the disease. According to Dr. Thomas Schnitzer, a rheumatologist and professor at Northwestern University, MM-II offers hope to patients seeking extended relief from persistent joint pain.
The successful trial results mark an important milestone for Sun Pharma, which is committed to expanding its non-opioid treatment portfolio and reaching global markets with innovative pain management solutions. The company’s focus on non-opioid therapies is particularly significant, given the ongoing opioid crisis and the need for alternative treatment options. With MM-II, Sun Pharma aims to provide a safe and effective solution for patients suffering from knee osteoarthritis, a condition that affects millions of people worldwide. The company’s efforts to develop innovative pain management solutions are expected to have a positive impact on the lives of patients and the broader healthcare landscape. Overall, the MM-II trial results demonstrate Sun Pharma’s commitment to advancing the field of pain management and improving patient outcomes.
Yemeni Woman, 63, Regains Mobility After 5-Year Struggle, Thanks to Successful Robot-Assisted Bilateral Knee Replacement Surgery at Fortis Bannerghatta – APN News
A 63-year-old woman from Yemen has successfully undergone a robot-assisted bilateral knee replacement surgery at Fortis Hospital, Bannerghatta, in Bengaluru, India. The surgery has enabled her to regain mobility after being bedridden for five years due to severe knee pain.
The patient, who had been suffering from osteoarthritis, had tried various treatments in her home country without finding relief. Her condition had worsened over time, leaving her unable to walk or perform daily activities.
The robotic-assisted knee replacement surgery was performed by a team of experienced orthopedic surgeons at Fortis Hospital. The surgery utilized advanced robotic technology to ensure precise bone cutting and accurate implant placement, resulting in a more natural feel and movement of the knee joint.
The patient’s journey to recovery began with a thorough evaluation and preparation, including pre-operative rehabilitation and counseling. The surgical team used a CT scan to create a personalized 3D model of the patient’s knee joint, allowing for precise planning and execution of the surgery.
The robot-assisted surgery took approximately two hours to complete, and the patient was able to walk with support within 24 hours of the operation. The patient’s progress was closely monitored by the medical team, and she was provided with post-operative physiotherapy and rehabilitation to ensure a smooth recovery.
The successful outcome of the surgery has given the patient a new lease on life, enabling her to regain mobility and independence. The patient expressed her gratitude to the medical team at Fortis Hospital, stating that she is now able to perform daily activities with ease and is looking forward to returning to her normal life.
The use of robotic technology in knee replacement surgery has revolutionized the field of orthopedics, offering numerous benefits, including improved accuracy, reduced blood loss, and faster recovery times. The success of this surgery highlights the expertise and capabilities of the medical team at Fortis Hospital, Bannerghatta, in providing world-class healthcare services to patients from around the world.
The patient’s case is a testament to the advancements in medical technology and the importance of seeking specialized medical care for complex conditions. With the help of robotic-assisted surgery, patients can now regain mobility and quality of life, even after years of suffering from debilitating conditions.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.